Lyell Immunopharma, Inc. — Director's Dealing 2023

Mar 1, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2023-02-24

Reporting Person: Albertson Tina M. (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-24	Option (right to buy)	$2.13	A	700000	Acquired	2033-02-23	Common Stock (700000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4049	Direct

Footnotes

F1: Includes 2,495 shares acquired on May 18, 2022 and 1,554 shares acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan.

F2: 12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following
forty-two months.